Basilea wins $89M contract for antibiotic work; Karolinska invests in biotech startup;

 @FierceBiotech: Astellas bites off $490M deal to develop muscle drugs with Cytokinetics. News | Follow @FierceBiotech

 @JohnCFierce: Bayer beefs up cancer drug pipeline with $520M armed antibody deal with Seattle Genetics. Story | Follow @JohnCFierce

 @RyanMFierce: Where were the breakthrough drugs for #diabetes at 2013 ADA? Report | Follow @RyanMFierce

> Switzerland's Basilea Pharmaceutica has won a BARDA contract worth up to $89 million to develop a new antibiotic. Release

> Karolinska Development has invested in Forendo Pharma Oy, a new drug development company based in Finland, together with Novo Seeds and Finnvera. The company is working on research from the University of Turku related to endometriosis and low testosterone levels. The total investment is expected to reach 10 million euros over three years. Release

> A team of outside experts has been taking steps to help Impax Laboratories get back on track after manufacturing issues sidetracked a key drug application and a key partnership with GlaxoSmithKline ($GSK). The company earlier this month said it would lay off 10% of its workforce to save money and now it says co-founder and CEO Larry Hsu is stepping down to make room for new leadership. Story

Medical Device News

 @FierceMedDev: Acutus hauls in $21M for a-fib imaging. Article | Follow @FierceMedDev

 @DamianFierce: Not to be outdone by J&J, Medtronic is starting an artificial pancreas study of its own. News | Follow @DamianFierce

 @MichaelGFierce: EnteroMedics files with FDA despite obesity-device trial flop. News | Follow @MichaelGFierce

> CardioFocus kicks off EU atrial fibrillation trial. Item

> Study: Boston Scientific's S-ICD safer than standard implants. More

Pharma News

 @FiercePharma: Eisai pulls seizure drug Fycompa in Germany to protest "appalling" pricing decision. Article | Follow @FiercePharma

 @EricPFierce: Impax CEO Larry Hsu, whose company has been sidetracked by FDA manufacturing issues, is retiring. Story | Follow @EricPFierce

 @CarlyHFierce: GSK CEO Andrew Witty's M&A aim: Sell more, buy less. Story | Follow @CarlyHFierce

> Merck wins Indian injunction against Januvia copycats. Item

> U.S. Supreme Court protects generic drugmakers in 5-4 ruling. News

> Ranbaxy reportedly has FDA issues at Mohali. More

Biotech Research News

 @EmilyMFierce: Lack of gene could predict earlier onset, severity of multiple sclerosis. Article | Follow @EmilyMFierce

> RNA molecule could reduce fat in bloodstream, regulate high cholesterol. More

> New target could be key to preventing epilepsy. Article

> Virus combo kills brain tumor cells in preclinical model. Story

> Penn scientists create human-cell model of pancreatic cancer. Article

> Antioxidant improves motor functions in mice with Parkinson's. Item

Pharma Manufacturing News

> India court quashes lawsuit against Ranbaxy plants. Item

> Pfizer quells fears of cuts at Ireland plant that makes Viagra. More

> Impax to get new CEO as it tries to right manufacturing issues. Article

> U.S. gets EU waiver on APIs in the nick of time. Story

And Finally… Investigators say that even a modest amount of weight loss will prevent some serious health risks spurred by diabetes. Story

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.